Nothing Special   »   [go: up one dir, main page]

ATE447969T1 - Verfahren zur behandlung der schädigung des zentralnervensystems durch ischämie oder durch hämorrhagie mit antagonisten von alpha4 integrin - Google Patents

Verfahren zur behandlung der schädigung des zentralnervensystems durch ischämie oder durch hämorrhagie mit antagonisten von alpha4 integrin

Info

Publication number
ATE447969T1
ATE447969T1 AT00984395T AT00984395T ATE447969T1 AT E447969 T1 ATE447969 T1 AT E447969T1 AT 00984395 T AT00984395 T AT 00984395T AT 00984395 T AT00984395 T AT 00984395T AT E447969 T1 ATE447969 T1 AT E447969T1
Authority
AT
Austria
Prior art keywords
nervous system
central nervous
hemorrhagia
ischemia
antagonists
Prior art date
Application number
AT00984395T
Other languages
English (en)
Inventor
Jane Relton
Roy Lobb
Eric Whalley
Steve Adams
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Application granted granted Critical
Publication of ATE447969T1 publication Critical patent/ATE447969T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Genetics & Genomics (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AT00984395T 1999-12-16 2000-12-14 Verfahren zur behandlung der schädigung des zentralnervensystems durch ischämie oder durch hämorrhagie mit antagonisten von alpha4 integrin ATE447969T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17126599P 1999-12-16 1999-12-16
PCT/US2000/033942 WO2001043774A1 (en) 1999-12-16 2000-12-14 Methods of treating central nervous system ischemic or hemorrhagic injury using anti alpha4 integrin antagonists

Publications (1)

Publication Number Publication Date
ATE447969T1 true ATE447969T1 (de) 2009-11-15

Family

ID=22623149

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00984395T ATE447969T1 (de) 1999-12-16 2000-12-14 Verfahren zur behandlung der schädigung des zentralnervensystems durch ischämie oder durch hämorrhagie mit antagonisten von alpha4 integrin

Country Status (11)

Country Link
US (1) US20020197233A1 (de)
EP (3) EP2140881B1 (de)
JP (3) JP2003517023A (de)
AT (1) ATE447969T1 (de)
AU (1) AU783110B2 (de)
CA (1) CA2394431C (de)
DE (1) DE60043308D1 (de)
DK (2) DK2140881T3 (de)
ES (2) ES2335643T3 (de)
NZ (1) NZ519447A (de)
WO (1) WO2001043774A1 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2106864C1 (ru) * 1995-10-23 1998-03-20 Николай Серафимович Зефиров Средство для лечения болезни альцгеймера
DK1214091T3 (da) * 1999-09-14 2006-08-28 Biogen Idec Inc Terapier til kronisk nyresvigt under anvendelse af én eller flere integrinantagonister
US6960597B2 (en) * 2000-06-30 2005-11-01 Orth-Mcneil Pharmaceutical, Inc. Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists
FR2827174B1 (fr) * 2001-07-13 2004-08-06 Soc Extraction Principes Actif Utilisation de peptides pour augmenter l'adhesion cellulaire
EP1592387A4 (de) 2003-01-24 2009-05-06 Elan Pharm Inc Zusammensetzung für und behandlung von entmyelinierenden erkrankungen und paralyse durch verabreichung von remyelinierenden mitteln
EP1624846A2 (de) * 2003-05-06 2006-02-15 Syntonix Pharmaceuticals, Inc. Hemmung der arzneimittelbindung an serumalbumin
US20050176755A1 (en) * 2003-10-31 2005-08-11 Dyatkin Alexey B. Aza-bridged-bicyclic amino acid derivatives as alpha4 integrin antagonists
US20070179174A1 (en) * 2003-12-08 2007-08-02 Bachurin Sergei O Methods and compositions for slowing aging
RU2283108C2 (ru) * 2003-12-08 2006-09-10 Сергей Олегович Бачурин ГЕРОПРОТЕКТОР НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО(4,3-b) ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ
CA2555365A1 (en) 2004-02-06 2005-08-25 Elan Pharmaceuticals, Inc. Methods and compositions for treating tumors and metastatic disease
JP2007522224A (ja) * 2004-02-10 2007-08-09 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ α４インテグリン拮抗薬としてのピリダジノン尿素
US8518021B2 (en) * 2004-05-27 2013-08-27 Baxter International Inc. Apparatus and method for therapeutic delivery of medication
WO2006023530A2 (en) * 2004-08-16 2006-03-02 Massachusetts Institute Of Technology Compositions and methods for enhancing structural and functional nervous system reorganization and recovery
US20070117834A1 (en) * 2005-10-04 2007-05-24 David Hung Methods and compositions for treating Huntington's disease
US8410115B2 (en) * 2006-02-28 2013-04-02 Elan Pharmaceuticals, Inc. Methods of treating inflammatory and autoimmune diseases with alpha-4 inhibitory compounds
SI2676967T1 (sl) 2006-02-28 2020-01-31 Biogen Ma Inc. Metode zdravljenja vnetne in avtoimunske bolezni z natalizumabom
EA016626B1 (ru) 2006-03-03 2012-06-29 Элан Фамэсьютикэлс, Инк. Способ лечения натализумабом воспалительного и/или аутоиммунного заболевания (варианты)
AU2007267579B2 (en) * 2006-05-25 2013-05-30 Biogen Ma Inc. Methods of treating stroke
WO2010072228A1 (en) 2008-12-22 2010-07-01 Xigen S.A. Novel transporter constructs and transporter cargo conjugate molecules
WO2011020874A1 (en) 2009-08-20 2011-02-24 Inserm (Institut National De La Sante Et De La Recherche Medicale) Vla-4 as a biomarker for prognosis and target for therapy in duchenne muscular dystrophy
SG181653A1 (en) 2010-01-11 2012-07-30 Biogen Idec Inc Assay for jc virus antibodies
US11287423B2 (en) 2010-01-11 2022-03-29 Biogen Ma Inc. Assay for JC virus antibodies
US9150618B2 (en) 2010-10-14 2015-10-06 Xigen Inflammation Ltd. Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases
CN103635803A (zh) 2011-05-31 2014-03-12 比奥根艾迪克Ma公司 评估进行性多灶性白质脑病风险的方法
JPWO2013001819A1 (ja) * 2011-06-30 2015-02-23 株式会社 免疫生物研究所 可溶性インテグリンα４変異体
WO2013091670A1 (en) * 2011-12-21 2013-06-27 Xigen S.A. Novel jnk inhibitor molecules for treatment of various diseases
US10119976B2 (en) 2013-05-28 2018-11-06 Biogen Ma Inc. Method of assessing risk of PML
JP2016523274A (ja) 2013-06-26 2016-08-08 ザイジェン インフラメーション リミテッド 種々の疾患を処置するためのｊｎｋシグナル伝達経路の新規の細胞透過性ペプチド阻害剤の使用
WO2015197097A1 (en) 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases
WO2014206427A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2016149248A1 (en) * 2015-03-15 2016-09-22 Emory University N-methyl-d-aspartate receptor (nmdar) potentiators, pharmaceutical compositions, and uses related thereto
AU2019373242B2 (en) 2018-10-30 2023-07-13 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
US11179383B2 (en) 2018-10-30 2021-11-23 Gilead Sciences, Inc. Compounds for inhibition of α4β7 integrin
EP3873900A1 (de) 2018-10-30 2021-09-08 Gilead Sciences, Inc. Imidazopyridinderivate als alpha4beta7-integrininhibitoren
MX2021005050A (es) 2018-10-30 2021-06-15 Gilead Sciences Inc Derivados de quinolina como inhibidores de integrina alfa4beta7.
WO2021030438A1 (en) 2019-08-14 2021-02-18 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
IL47468A (en) 1975-06-12 1979-05-31 Rehovot Res Prod Process for the cross-linking of proteins using water soluble cross-linking agents
NZ215865A (en) 1985-04-22 1988-10-28 Commw Serum Lab Commission Method of determining the active site of a receptor-binding analogue
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
DE3852304T3 (de) 1987-03-02 1999-07-01 Enzon Labs Inc., Piscataway, N.J. Organismus als Träger für "Single Chain Antibody Domain (SCAD)".
US5011691A (en) 1988-08-15 1991-04-30 Stryker Corporation Osteogenic devices
US5266683A (en) 1988-04-08 1993-11-30 Stryker Corporation Osteogenic proteins
US5284756A (en) 1988-10-11 1994-02-08 Lynn Grinna Heterodimeric osteogenic factor
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5260210A (en) * 1989-09-27 1993-11-09 Rubin Lee L Blood-brain barrier model
US5192746A (en) 1990-07-09 1993-03-09 Tanabe Seiyaku Co., Ltd. Cyclic cell adhesion modulation compounds
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5260277A (en) 1990-09-10 1993-11-09 Tanabe Seiyaku Co., Ltd. Guanidinyl and related cell adhesion modulation compounds
WO1992008464A1 (en) 1990-11-15 1992-05-29 Tanabe Seiyaku Co. Ltd. Substituted urea and related cell adhesion modulation compounds
US5219990A (en) 1991-01-28 1993-06-15 Biogen, Inc. Papillomavirus e2 trans-activation repressors
JP3504263B2 (ja) 1991-11-04 2004-03-08 ジェネティックス・インスチチュート・リミテッド・ライアビリティ・カンパニー 組み換え型骨形態形成蛋白ヘテロダイマー、組成物および使用法
WO1993008823A1 (en) 1991-11-06 1993-05-13 Tanabe Seiyaku Co., Ltd. Guanidinyl and related cell adhesion modulation compounds
US5932214A (en) 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
JPH08505628A (ja) 1993-01-08 1996-06-18 田辺製薬株式会社 ペプチド型細胞接着阻害薬
JPH08507680A (ja) 1993-01-12 1996-08-20 バイオジェン インコーポレイテッド 組換え抗ｖｌａ４抗体分子
JP3593343B2 (ja) 1993-02-09 2004-11-24 バイオジェン インコーポレイテッド インシュリン依存型糖尿病の治療
AU693143B2 (en) 1993-12-06 1998-06-25 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using the same
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
CN1211123C (zh) * 1994-01-25 2005-07-20 雅典娜神经科学公司 抗白细胞粘附分子vla－4的人源化抗体
US5510332A (en) 1994-07-07 1996-04-23 Texas Biotechnology Corporation Process to inhibit binding of the integrin α4 62 1 to VCAM-1 or fibronectin and linear peptides therefor
CA2193508A1 (en) 1994-07-11 1996-01-25 Eugene D. Thorsett Inhibitors of leukocyte adhesion
US5811391A (en) 1994-08-25 1998-09-22 Cytel Corporation Cyclic CS-1 peptidomimetics, compositions and methods of using same
GB9524630D0 (en) 1994-12-24 1996-01-31 Zeneca Ltd Chemical compounds
US6306840B1 (en) 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
WO1996040781A1 (en) 1995-06-07 1996-12-19 Tanabe Seiyaku Co., Ltd. CYCLIC PEPTIDE INHIBITORS OF β1 AND β2 INTEGRIN-MEDIATED ADHESION
AU6311996A (en) 1995-07-06 1997-02-05 Zeneca Limited Peptide inhibitors of fibronectine
US6248713B1 (en) 1995-07-11 2001-06-19 Biogen, Inc. Cell adhesion inhibitors
DE19541844C1 (de) 1995-11-09 1997-07-24 Gsf Forschungszentrum Umwelt Verfahren zur Herstellung von menschlichen Antikörpern und deren Verwendung
CA2291778A1 (en) 1997-05-29 1998-12-03 Merck & Co., Inc. Heterocyclic amide compounds as cell adhesion inhibitors
IL133635A0 (en) * 1997-07-31 2001-04-30 Elan Pharm Inc Benzyl compounds which inhibit leukocyte adhesion mediated by vla-4
US6153653A (en) * 1997-11-26 2000-11-28 Protarga, Inc. Choline compositions and uses thereof
IL139321A0 (en) * 1999-03-03 2001-11-25 Biogen Inc Methods and compositions for modulating lipid metabolism
US9501219B2 (en) 2012-01-25 2016-11-22 Oracle International Corporation 2D line data cursor
US9713013B2 (en) 2013-03-15 2017-07-18 Elwha Llc Protocols for providing wireless communications connectivity maps
US9400266B2 (en) 2013-03-14 2016-07-26 Rosemount Analytical Inc. Gas chromatograph with improved operation
US9104862B2 (en) 2013-04-01 2015-08-11 Uniquesoft, Llc Secure computing device using new software versions

Also Published As

Publication number Publication date
ES2415708T3 (es) 2013-07-26
DK1242118T3 (da) 2010-01-11
ES2335643T3 (es) 2010-03-31
DE60043308D1 (de) 2009-12-24
WO2001043774A1 (en) 2001-06-21
US20020197233A1 (en) 2002-12-26
JP2012167128A (ja) 2012-09-06
CA2394431C (en) 2015-06-30
EP2140881A1 (de) 2010-01-06
DK2140881T3 (da) 2013-05-06
EP1242118A1 (de) 2002-09-25
EP2332578A1 (de) 2011-06-15
NZ519447A (en) 2004-03-26
EP2140881B1 (de) 2013-04-17
AU783110B2 (en) 2005-09-22
AU2102001A (en) 2001-06-25
JP2012017345A (ja) 2012-01-26
JP2003517023A (ja) 2003-05-20
EP1242118B1 (de) 2009-11-11
JP5519612B2 (ja) 2014-06-11
CA2394431A1 (en) 2001-06-21

Similar Documents

Publication Publication Date Title
ATE447969T1 (de) Verfahren zur behandlung der schädigung des zentralnervensystems durch ischämie oder durch hämorrhagie mit antagonisten von alpha4 integrin
DE60039783D1 (de) Lfa-1 antagonisten und tnf-alpha antagonisten zur
DE69733611D1 (de) Verfahren und potenzierte zusammensetzung zur behandlung von migräne
DE602004010381D1 (de) Verfahren und vorrichtung zur behandlung von wasser für eine einpressbohrung
DE60122532D1 (de) Verfahren zur behandlung von mehreren bohrlochintervallen
DE69525847D1 (de) Zusammensetzungen von opioid antagonisten mit selektiven serotonin-aufnahme inhibitoren, zur behandlung von alkoholismus und alkohoabhängigkeit
DE69928237D1 (de) Verfahren zur behandlung von abwasser zur entfernung von organischen stoffen und stickstoff,
DE60104188D1 (de) Verfahren und vorrichtung zur behandlung von wasser/abwasser
ATE259245T1 (de) Verfahren zur behandlung von beweggungsstörungen
DE60227095D1 (de) Zusammensetzungen und verfahren zur behandlung von abgebundenem gips
DE60120520D1 (de) Verfahren zur behandlung von abwasser
DE69501817D1 (de) Verfahren zur behandlung von parasitären infektionen unter verwendung von ige-antagonisten
DE60045416D1 (de) Verfahren zur behandlung von mikroelektroniksubstraten
ATE318820T1 (de) Verfahren zur behandlung von mit p38-kinase assoziierten leiden und pyrrolotriazin- verbindungen als kinaseinhibitoren.
ATE280744T1 (de) Verfahren zur herstellung von n-((aliphatisch oder aromatisch)carbonyl)-2-aminoacetamid- verbindungen und deren cyclisierung
ATE288675T1 (de) Verfahren und vorrichtung zum schwenken der abteiler von mehrteiligen landwirtschaftlichen erntemaschinen
DE60033486D1 (de) Verfahren und Vorrichtung zur Behandlung von Perfluorverbindungen enthaltenden Gasen
ATE277997T1 (de) Verfahren zur stabilisierung von textilweichmacherzusammensetzungen
DE10084174T1 (de) Verfahren zur Verpackung von IC-Vorrichtungen, welche Hohlräume neben aktiven Gebieten enthalten, und verwandter Strukturen
DE59705243D1 (de) Verfahren zur Herstellung von N-substituierten cyclischen Aminen
DE50104023D1 (de) Verfahren zum auffinden von verbindungen, welche zur behandlung und/oder prophylaxe von obesitas geeignet sind
ATE381938T1 (de) Verwendungen zur behandlung von fsh-verbundenen zuständen mit gnrh antagonisten
DE60018707D1 (de) Anti-androgene und verfahren zur behandlung von krankheiten
DE60103939D1 (de) Gehärteter Kautschuk und Verfahren zur Behandlung von gehärtetem Kautschuk
DE60218203D1 (de) Verbindungen und verfahren zur behandlung einer hyperaktiven blase

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties